Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23707762 | 1.00 | DRD1 (0.39) | DRD1DRD3CHRM2ADRA2ACHRM1 | |
| SCHEMBL24477569 | 1.00 | DRD1 (0.39) | DRD1DRD3CHRM2ADRA2ACHRM1 | |
| Hydrochloric Acid SCHEMBL30212806 | 0.98 | SMN1; SMN2 (0.39) | DRD1DRD3CHRM2ADRA2ACHRM1 | |
| Acetic Acid SCHEMBL30330233 | 0.89 | GFER (0.47) | CYP2D6LSSSMN1; SMN2GFERCHRNB2 | |
| SCHEMBL21283150 | 0.88 | CYP1A2 (0.44) | DRD1DRD3CHRM2ADRA2ACHRM1 | |
| SCHEMBL8507191 | 0.87 | CYP1A2 (0.56) | DRD1DRD3CHRM2ADRA2ACHRM1 | |
| SCHEMBL13479302 | 0.86 | — | — | |
| SCHEMBL23251417 | 0.86 | — | — | |
| SCHEMBL255098 | 0.86 | — | — | |
| SCHEMBL19454711 | 0.85 | LSS (0.51) | DRD1DRD3CHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117543086-A | Electrolyte for lithium secondary battery including ionic liquid and cosolvent and lithium secondary battery including the same | 现代自动车株式会社 | 2024-02-09 | — | — | CN | claimed |
| CN-117543086-A | Electrolyte for lithium secondary battery including ionic liquid and cosolvent and lithium secondary battery including the same | 现代自动车株式会社 | 2024-02-09 | — | — | CN | disclosed |
| US-20230340435-A1 | BASE EDITING OF ANGPTL3 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE | VERVE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230257415-A1 | COMPOUNDS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2023-08-17 | — | — | US | disclosed |
| EP-4180432-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| CN-106463711-B | Dendrite inhibiting electrolyte for metal-based batteries | 康奈尔大学 | 2021-05-07 | — | — | CN | disclosed |
| EP-3798214-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2021-03-31 | — | — | EP | disclosed |
| EP-3224258-B1 | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | GENENTECH INC (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3030555-B1 | NOVEL PYRAZINE AMIDE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2019-01-30 | — | — | EP | disclosed |
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| EP-2084765-A2 | SECONDARY ELECTROCHEMICAL CELL WITH HIGH RATE CAPABILITY | Valence Technology, INC. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090036489-A1 | Novel Cyclic Aminophenylalkanoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20080261113-A1 | SECONDARY ELECTROCHEMICAL CELL WITH HIGH RATE CAPABILITY | VALENCE TECHNOLOGY, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008061174-A9 | SECONDARY ELECTROCHEMICAL CELL WITH HIGH RATE CAPABILITY | VALENCE TECHNOLOGY INC (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008061174-A2 | SECONDARY ELECTROCHEMICAL CELL WITH HIGH RATE CAPABILITY | VALENCE TECHNOLOGY, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008032858-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-20 | — | — | WO | disclosed |
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | DRD1 4787/4885DRD3 4436/4885CHRM2 1088/4885 |
| US-20230340435-A1 | BASE EDITING OF ANGPTL3 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE | LDLR, PCSK9, APOB | DRD1 4800/4885DRD3 4780/4885CHRM2 4795/4885 |
| US-20230257415-A1 | COMPOUNDS FOR TREATING CNS DISORDERS | PMP22, SLC18A2, SLC6A1 | DRD1 921/4885DRD3 885/4885CHRM2 415/4885 |
| US-20090036489-A1 | Novel Cyclic Aminophenylalkanoic Acid Derivative | PPARA, PPARD, PPARG | DRD1 2730/4885DRD3 2828/4885CHRM2 1907/4885 |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | NR2C2, NR4A3, NR0B2 | DRD1 43/4885DRD3 10/4885CHRM2 988/4885 |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | DRD1 4884/4885DRD3 4836/4885CHRM2 4869/4885 |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | PPARA, PPARG, PPARD | DRD1 917/4885DRD3 1516/4885CHRM2 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.